Soft Landing, Hard Numbers: Why a 57,000‑Job Economy May Love $RIVN, $SMWB, and $MODD

The market walked into June’s jobs report braced for a slowdown and still managed to be surprised by how leisurely the hiring pace has become—with a few high‑conviction growth stories quietly stealing the show in EVs, digital data, and med‑tech.

A “Goldilocks‑ish” Jobs Report Sets the Macro Stage

The US added 57,000 jobs in June, roughly half of what economists were expecting and a sharp downshift from May’s revised 129,000 gain. The unemployment rate, however, ticked down to 4.2%, its lowest level in a year, helped by a softer labor force participation rate and still‑muted layoffs. Professional and business services, social assistance, and healthcare did the heavy lifting, while leisure and hospitality actually shed 61,000 jobs amid weaker‑than‑usual seasonal hiring. Average hourly earnings rose about 3.5% year‑over‑year, a pace consistent with gradually cooling inflation rather than a wage‑price spiral. For equity investors, that mix—slower job creation, lower jobless rate, moderating wages—lands in the “slower but still standing” camp, reinforcing the case for a patient but ultimately more accommodative Fed rather than a policy emergency. In other words: macro headwinds are now more of a stiff breeze than a hurricane, which tends to favor stock pickers over index tourists..

Rivian’s Quiet Flex: Execution Over Hype

While the labor market eased off the accelerator, Rivian Automotive Inc. (NASDAQ:RIVN) used the quarter to demonstrate something that the EV space has been short on lately: consistent operational execution. The company produced 12,613 vehicles and delivered 12,194 units in Q2 2026, topping investor expectations and showing that its manufacturing ramp is becoming less of an experiment and more of a habit. Those results gave Rivian enough confidence to raise its 2026 delivery outlook to a range of 65,000–70,000 vehicles, up from a prior 62,000–67,000 forecast. The stock responded with a roughly 5% pop to around 18 dollars as investors rewarded the uncommon combination of volume growth, guidance discipline, and the prospect of operating leverage as the R2 platform ramps.

In a market that has punished EV hopefuls for over‑promising and under‑delivering, Rivian’s narrative is shifting from “story stock” to “execution story”—still high beta, but now with unit economics and guidance that increasingly have to be modeled rather than imagined. For portfolio managers, that’s the difference between a speculative flier and a name that can sit in an active growth sleeve with a thesis tied to tangible milestones: production scale, margin trajectory, and product mix.

Similarweb: Turning Data Exhaust into Durable ARR

If Rivian is about tangible steel and batteries, Similarweb Ltd. (NYSE:SMWB) is betting that digital exhaust—traffic, engagement, conversion patterns—is the new blue‑chip raw material for decision‑makers. The company announced that it has surpassed 300 million dollars in annual recurring revenue and signed two multi‑year enterprise contracts, each carrying seven‑figure ARR commitments. Collectively, those new deals represent about 47 million dollars in total contract value to be recognized over the next three years, and were inked during Q2 2026. Shares of Similarweb jumped roughly 12% to just under 5 dollars on the news, as investors recalibrated the company from “niche analytics provider” toward a scaled digital intelligence platform with growing enterprise stickiness. The strategic punchline is that these contracts are incremental to large deals deferred from late 2025, one of which was already signed in Q1 2026, reinforcing management’s confidence in the full‑year 2026 guidance. For growth‑oriented investors looking for under‑followed AI‑adjacent names, SMWB offers something of a rarity: a recurring‑revenue model built on data that customers increasingly view as mission‑critical, plus multi‑year visibility that can smooth out cyclical macro noise..

Modular Medical: From De‑Risking to Deployment

On the healthcare frontier, Modular Medical, Inc. (NASDAQ:MODD) is attempting to re‑write how insulin‑dependent patients experience daily therapy, and investors are starting to get a first look at real‑world commercialization. Following FDA 510(k) clearance in April for its Pivot tubeless insulin patch pump—a major de‑risking milestone—the company has now begun shipping Pivot starter kits to multiple endocrinology practices. The devices have initially headed to physician offices for training and early patient introductions, with a phased commercial rollout planned across select high‑volume practices and metropolitan markets through late 2026. Management has framed the opportunity as a way to convert the roughly 70% of insulin‑dependent adults who still rely on multiple daily injections because pumps have historically been too complex, cumbersome, or costly. With initial shipments underway and commercial availability declared, Modular Medical is effectively transitioning from a development‑stage med‑tech story to a commercial‑stage one, shifting the investor debate from “will they get approved?” to “how fast can they scale adoption?” For small‑cap healthcare specialists, MODD now screens as a leveraged play on a very large, very under‑penetrated diabetes technology market, with meaningful catalysts around adoption data and geographic expansion.

Where the Macro Meets the Micro for Investors

The June jobs report keeps the “soft landing” narrative intact, but with enough wobble to justify continued Fed vigilance and a gradual, data‑dependent path toward easier policy. That environment tends to reward companies that can create their own growth cycle—through execution, product differentiation, or long‑duration contracts—rather than relying on a roaring GDP backdrop to bail them out. Rivian (RIVN) is trying to become the EV player that hits its marks while peers miss; Similarweb (SMWB) is converting a secular data and AI tailwind into multi‑year ARR visibility; and Modular Medical (MODD) is stepping into revenue mode in a chronic‑care market where incumbency is strong but dissatisfaction is widespread. For investors navigating a slower‑growth, still‑elevated‑rate world, these are the kinds of names that can turn a “meh” macro tape into a portfolio that still has something to talk about at the next investment committee meeting.

The Sources

1. June jobs report: US payrolls rose by 57,000, missing expectations – Yahoo Finance
   https://finance.yahoo.com/economy/article/june-jobs-report-us-payrolls-rose-by-57000-missing-expectations-190000748.html
2. US payrolls rose by 57,000 in June, missing expectations – Yahoo Canada Finance
   https://ca.finance.yahoo.com/news/june-jobs-report-us-payrolls-rose-by-57000-in-june-missing-expectations-190000748.html
3. Jobs report June 2026 – CNBC
   https://www.cnbc.com/2026/07/02/jobs-report-june-2026-.html
4. Employers added 57,000 jobs in June, far below forecasts – CBS News
   https://www.cbsnews.com/news/june-jobs-report-57000-jobs-hiring-slows
5. US economy adds 57,000 jobs in June, below expectations – Yahoo Finance (video recap)
   https://finance.yahoo.com/video/us-economy-adds-57000-jobs-in-june-below-expectations-123833694.html
6. Rivian raises 2026 delivery outlook while Lucid misses expectations – CNBC
   https://www.cnbc.com/2026/07/02/rivian-lucid-q2-deliveries-demand.html
7. Rivian releases Q2 2026 production and delivery figures, raises full‑year outlook – Press release (Business Wire via Futu)
   https://news.futunn.com/en/post/75459235/press-release-rivian-releases-q2-2026-production-and-delivery-figures
8. Rivian raises 2026 delivery forecast after stronger second‑quarter performance (RIVN) – Yahoo Finance
   https://finance.yahoo.com/markets/stocks/articles/rivian-raises-2026-delivery-forecast-125225595.html
9. Rivian raises 2026 delivery guidance after Q2 beat – Grafa
   https://grafa.com/en/news/united-states/rivian-q2-2026-deliveries-guidance-increase
10. Rivian tops Q2 delivery numbers and raises full‑year 2026 outlook – Electrek
    https://electrek.co/2026/07/02/rivian-tops-q2-delivery-numbers-and-raises-full-year-2026-outlook
11. Rivian raises EV sales forecast as Q2 production ramps up – TechCrunch
    https://techcrunch.com/2026/07/02/rivian-thinks-it-will-sell-more-evs-than-expected-this-year
12. Rivian is up 5% today: Is it outperforming other EV stocks like Tesla and Lucid? – 24/7 Wall St.
    https://247wallst.com/investing/2026/07/02/rivian-is-up-5-today-is-it-outperforming-other-ev-stocks-like-tesla-and-lucid
13. Similarweb secures multi‑year, seven‑figure ARR contracts worth approximately $47 million – Business Wire
    https://www.businesswire.com/news/home/20260615625728/en/Similarweb-Secures-Multi-Year-Seven-Figure-ARR-Contracts-Worth-Approximately-47-Million-in-Total-Contract-Value
14. Similarweb shares rise after new multi‑year contracts – MarketWatch
    https://www.marketwatch.com/story/similarweb-shares-rise-after-new-multi-year-contracts-161a19c1
15. Modular Medical receives FDA 510(k) clearance for Pivot tubeless insulin patch pump – Nasdaq press release
    https://www.nasdaq.com/press-release/modular-medical-receives-fda-510k-clearance-pivot-tubeless-insulin-patch-pump-2026-04
16. Modular Medical announces shipment of Pivot tubeless patch pumps – Morningstar / ACCESSWIRE
    https://www.morningstar.com/news/accesswire/1181878msn/modular-medical-announces-shipment-of-pivot-tubeless-patch-pumps
17. Modular Medical announces commercial availability of Pivot tubeless insulin patch pump ahead of commercial expansion – The Globe and Mail (ACCESS Newswire)
    https://www.theglobeandmail.com/investing/markets/markets-news/access-newswire/2624616/modular-medical-announces-commercial-availability-of-pivot-tubeless-insulin-patch-pump-ahead-of-commercial-expansion